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Summary
Type B insulin resistance syndrome (TBIR) is characterised by the rapid onset of severe insulin resistance due to circulating 
anti-insulin receptor antibodies (AIRAs). Widespread acanthosis nigricans is normally seen, and co-occurrence with 
other autoimmune diseases is common. We report a 27-year-old Caucasian man with psoriasis and connective tissue 
disease who presented with unexplained rapid weight loss, severe acanthosis nigricans, and hyperglycaemia punctuated 
byfastinghypoglycaemia.Severeinsulinresistancewasconfirmedbyhyperinsulinaemiceuglycaemicclamping,and
immunoprecipitationassaydemonstratedAIRAs,confirmingTBIR.Treatmentwithcorticosteroids,metforminand
hydroxychloroquine allowed withdrawal of insulin therapy, with stabilisation of glycaemia and diminished signs of insulin 
resistance; however, morning fasting hypoglycaemic episodes persisted. Over three years of follow-up, metabolic control 
remained satisfactory on a regimen of metformin, hydroxychloroquine and methotrexate; however, psoriatic arthritis 
developed.ThiscaseillustratesTBIRasararebutsevereformofacquiredinsulinresistanceanddescribesaneffective
multidisciplinary approach to treatment.
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Learning points:
 • We describe an unusual case of type B insulin resistance syndrome (TBIR) in association with mixed connective 
tissue disease and psoriasis.
 • Clinical evidence of severe insulin resistance was corroborated by euglycaemic hyperinsulinaemic clamp, and anti-
insulinreceptorautoantibodieswereconfirmedbyimmunoprecipitationassay.
 • Treatment with metformin, hydroxychloroquine and methotrexate ameliorated extreme insulin resistance.
Background
Type B insulin resistance syndrome (TBIR) is a rare 
autoimmune disorder characterised by the development 
of anti-insulin receptor antibodies (AIRA). It most 
commonly leads to extreme insulin resistance with severe 
hyperglycaemia and weight loss; however, hypoglycaemia 
may be seen, especially where antibody titre is low (1). TBIR 
is commonly associated with underlying autoimmune 
diseases, such as systemic lupus erythematosus (SLE), 
various connective tissue diseases, interstitial lung disease 
or organ-specific dermatological, haematological, or 
hepatic disorders (1, 2, 3). Here, we present an unusual 
case of TBIR associated with connective tissue disease 
and psoriasis, with insulin resistance confirmed by 
hyperinsulinaemic euglycaemic clamp and stabilised with 
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a regimen of corticosteroids, hydroxychloroquine and 
metformin.
Case presentation
A 27-year-old Caucasian man with a 2-year history of 
psoriasis was hospitalised because of an unexplained weight 
loss of 20-kg in one year. He also reported fatigue and a 
new onset of Raynaud’s phenomenon. One year earlier, 
he had undergone haematological evaluation because 
of peripheral lymphadenopathy and enlarged parotid 
glands, with results deemed consistent with viral infection. 
Lymphoproliferative disease was excluded on the basis of 
lymph node histopathological examination. There was no 
family history of diabetes or autoimmune disease.
Investigation
Physical examination revealed malnutrition. Height was 
180 cm and weight 53.3 kg (BMI 16.4 kg/m2). There was 
widespread acanthosis nigricans in the axillae, antecubital 
fossae, groins, and on the thumbs (Fig. 1). Sclerodactyly, 
psoriatic lesions, enlarged parotid glands, palpable 
cervical and axillary lymph nodes, and tachycardia were 
also noted. Dual energy X-ray absorptiometry revealed a 
paucity of subcutaneous and visceral fat and decreased lean 
body mass (Fig. 2). Table 1 shows laboratory findings on 
admission. Full blood count revealed anaemia, leucopaenia 
with lymphopaenia, and thrombocytopaenia. Blood 
glucose concentration on admission was 20.1 mmol/L with 
glycated haemoglobin (HbA1c) 12.4% (112 mmol/mol) 
and associated glycosuria. From day 17 of observation, 
the patient developed asymptomatic morning fasting 
hypoglycaemia, more frequently observed in the further 
Figure 1
The extent of acanthosis nigricans in the patient on admission.
Figure 2
Distribution of adipose tissue obtained by dual energy X-ray 
absorptiometry.
A Łebkowska and others ID: 20-0027; August 2020
DOI: 10.1530/EDM-20-0027
Type B insulin resistance 
syndrome
https://edm.bioscientifica.com/ 3
course of treatment (glycaemic nadir 1.5 mmol/L). The 
concentration of endogenous insulin, measured after the 
reduction of insulin doses, when the patient required 
only low doses of prandial insulin, exceeded 300 μIU/mL. 
Fasting C-peptide concentration was within the normal 
range and increased adequately in glucagon stimulation 
test (0 min: 2.87 ng/mL, 6 min: 4.56 ng/mL). Plasma 
adiponectin concentration, assayed as previously described, 
was 13.8 mg/L (4). Insulin autoantibodies, glutamic acid 
decarboxylase autoantibodies and insulinoma-associated-2 
autoantibodies were negative. Immunoprecipitation assay 
revealed anti-insulin receptor antibodies in two separate 
blood samples, confirming TBIR (Fig. 3). Hyperinsulinaemic 
euglycaemic clamping was performed in accordance with 
the protocol by DeFronzo et  al. (5). The rate of whole-
body glucose uptake (M value) was calculated as the mean 
glucose infusion rate during the last 40 min of the clamp, 
corrected for the glucose space and normalised for fat-free 
mass (FFM). The clamp confirmed severe insulin resistance 
with an M value of 2.1 mg/kgFFM/min (the mean M value 
obtained in a cohort of 60 healthy normal-weight men was 
7.1 ± 2.4 mg/kgFFM/min (6)).
Due to clinical features of connective tissue disease, 
a wider autoimmune screen was undertaken. High titres 
of antinuclear antibodies and anti-ribonucleoprotein 
antibodies were found, with positive Ro52 and anti-dsDNA 
Table 1 Laboratoryfindingsonadmission.
Laboratory tests Normal values Results
HbA1c (mmol/mol) 26.8–44.3 112
Fasting glucose (mmol/L) 3.9–5.5 20.0
Fasting C-peptide (ng/mL) 0.78–5.19 2.87
C-peptide in glucagon test (6 min) (ng/mL) 4.56
Urine glucose Negative 1000 mg/dL
Urine protein Negative 25 mg/dL
Urine ketones Negative Negative
C-reactive protein (mg/L) 0.0–10.0 1.9
White blood cells (×103/μL) 4.0–10.0 2.84
Red blood cells (×106/μL) 4.5–6.0 4.09
Haemoglobin (g/dL) 14.0–18.0 12.5
Platelets (×103/μL) 130–350 115
Total protein (g/dL) 6.0–8.0 6.4
IgG4 (g/L) 0.08–1.40 1.14
Sodium (mmol/L) 136.0–145.0 134
Potassium (mmol/L) 3.5–5.1 4.52
Alanine aminotransferase (IU/L) 5.0–50.0 68
Aspartate aminotransferase (IU/L) 5.0–50.0 36
Triglycerides (mg/dL) <150 79
Total cholesterol (mg/dL) <190 109
LDL-cholesterol (mg/dL) <115 61
HDL-cholesterol (mg/dL) >45 34
Insulin autoantibodies (U/mL) <0.4 0.4
Anti-GAD antibodies (IU/mL) <10 <5
Anti-IA-2 antibodies (IU/mL) <10 <10
Anti-RNP/Sm antibodies Negative +++
Anti-Ro-52 antibodies Negative +++
Anti-MDA 5 antibodies Negative +
Anti-Ku antibodies Negative +
Anti-nuclear antibodies <1:100 1:6400
Anti-neutrophil cytoplasmic antibodies Negative Negative
Anti-citrullinated peptides antibodies Negative Negative
C3 complement (mg/L) 970.0–1576.0 430
C4 complement (mg/L) 162.0–445.0 64
Anti-tTg (U/mL) <0.3 0.2
Anti-dsDNA antibodies Negative +
Coombs direct test Negative Positive
Thyroid peroxidase antibodies (IU/mL) 0.0–5.61 1.26
Thyroglobulin antibodies (IU/mL) 0.0–4.11 2.61
GAD,glutamicaciddecarboxylase;IA-2,insulinoma-associatedprotein-2;MDA-5,melanomadifferentiation-associatedgene5;RNP,ribonucleoprotein;
tTg, tissue transglutaminase.
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antibodies. Direct Coombs test was positive, and serum 
complement concentrations were decreased. Collectively 
this led us to the diagnosis of mixed connective tissue 
disease. CT of the lungs and the abdomen, MRI of 
the brain, pulmonary function tests, and histological 
assessment of bone marrow, parotid glands and lymph 
nodes failed to demonstrate neoplasia.
Treatment
The treatment course is presented in Fig. 4. The patient 
was initially treated with i.v. insulin infusion, followed by 
intensive insulin therapy. This regimen did not improve 
blood glucose concentration despite daily insulin doses 
from 60 IU/24 h to 110 IU/24 h (>2 IU/kg of body 
weight). Metformin (850 mg three times a day) allowed 
gradual reduction of insulin doses (from 110 IU/24 h to 
40 IU/24 h in 10 days). Given the coexistence of TBIR 
and mixed connective tissue disease, a cycle of pulsed 
methylprednisolone therapy was administered (250 mg/
day for 3 days), followed by oral prednisone in decreasing 
doses for 1 month. Simultaneously, hydroxychloroquine 
(400 mg/day) was started and euglycaemia was maintained, 
which allowed withdrawal of insulin and reduction of 
metformin dose to 3 × 500 mg. Due to fasting morning 
hypoglycaemic episodes, the morning dose of metformin 
was stopped.
Outcome and follow-up
Six months after the initiation of treatment, weight 
had increased to 59.8 kg (BMI 18.5 kg/m2). Acanthosis 
nigricans and sclerodactyly also improved but did not 
remit entirely (Fig. 5). HbA1c decreased to 7.3% (56 mmol/
mol) with only rare episodes of fasting hypoglycaemia. 
Fasting insulin concentration remained elevated at 126 
µU/mL. The daily dose of metformin was reduced to 
1000 mg/day in two doses. Thirty-three months later, 
inflammation of the elbow and interphalangeal joints of 
both hands developed with the intensification of psoriatic 
lesions (Fig. 6). Methotrexate treatment was initiated as 
an adjunct to hydroxychloroquine. During this therapy, 
Figure 3
Detection of anti-insulin receptor autoantibodies. Anti-insulin receptor 
autoantibodies were detected by immunoprecipitation assay using input 
of serum diluted either 1:5 or 1:50 as indicated. Anti-insulin receptor 
probing of immunoprecipitated is shown. +ve control, positive control 
serum obtained from a patient with proven type B insulin resistance with 
high antibody titre. ‘‘CL6’ denotes lysate from Chinese Hamster Ovary 
Cells stably expressing human insulin receptor as an additional control. 
Times denote interval from initial presentation.
Figure 4
Daytimeglycaemicprofilesduringthecourseoftreatment.Thebloodglucoseconcentrationsof2consecutivedaysareshownforappropriate
intervention. MDI, multiple daily injections.
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weight gain increased further (BMI 19.7 kg/m2), with 
the disappearance of acanthosis nigricans, significant 
improvement of arthritis and reduction of psoriatic 
lesions. Fasting glucose concentration was 4.3 mmol/L.
Discussion
Type B insulin resistance is rare. The largest longitudinal 
cohort of 24 patients has been reported by researchers 
from the United States National Institutes of Health 
(NIH) (1). It occurs mainly in the fourth to sixth decade 
of life, usually against a background of a rheumatological 
illness, most commonly connective tissue disease, lupus 
erythematosus, or as a paraneoplastic manifestation (1, 
2, 7). We report a younger male Caucasian patient with 
typical symptoms of TBIR in association with mixed 
connective tissue disease and psoriasis. We assessed 
insulin sensitivity by hyperinsulinaemic euglycaemic 
clamp to confirm the severity of insulin resistance.
There is no pathognomonic clinical feature of TBIR, 
although rapid onset of extreme insulin resistance with 
widespread acanthosis nigricans, severe hyperglycaemia 
with attendant catabolic state and weight loss are 
characteristic. Type B insulin resistance syndrome is caused 
by AIRAs, which, based on rodent and cellular studies, act 
as agonists at the insulin receptor when the titre is low 
and as antagonists due to receptor downregulation when 
at high titre (8). This means that metabolic consequences 
of AIRAs are variable, ranging from extreme insulin 
resistance and hyperglycaemia in the first phase of the 
disease to recurrent fasting hypoglycaemia during early 
remission. Klubo-Gwiezdzinska   et al. confirmed that all 
studied patients with TBIR experienced hypoglycaemic 
episodes when AIRA titre decreased, which allowed 
to reduce insulin doses (9). Initial presentation with 
hypoglycaemia alone is rare and was observed in only 
13% of patients in the NIH cohort (1). Our patient started 
to develop fasting morning hypoglycaemia shortly after 
diabetes diagnosis. Despite reduction of insulin doses 
and eventually withdrawal of exogenous insulin, these 
episodes recurred. Thus, the suggestion of prolonged 
degradation of insulin–insulin receptor complexes or the 
coexistence of different populations of antibodies might 
be the possible pathomechanism (1).
 The biochemical triad of markedly elevated fasting 
insulin concentration, hyperadiponectinaemia and low/
normal fasting triglyceride concentrations was discussed 
as a ‘‘working" clinical definition of TBIR (10). Adiponectin 
level >7 mg/L in subjects with symptoms of severe insulin 
resistance had a 97% positive predictive value for defects 
of insulin receptor function (11). Our patient had high 
fasting insulin level, low triglycerides concentration and 
increased adiponectin concentration, which confirmed 
earlier findings.
Treatment of TBIR is challenging. The majority 
of reported cases of TBIR are associated with other 
autoimmune diseases, most often systemic lupus 
erythematosus or other connective tissue disease. To 
control hyperglycaemia at admission, the dose of insulin 
required intravenously in our patient was lower than 
presented in other cases, but was markedly higher than 
in "common" type 2 diabetes (7). Descriptions of use of 
metformin, sulphonylureas and thiazolidinediones in 
therapy of hyperglycaemia in TBIR have demonstrated 
variable efficacy (12, 13). In our patient, metformin 
allowed significant decrease in the dose of insulin.
The therapy requires intensive monitoring for side 
effects of immunosuppressive drugs and insulin titration 
due to glycaemic variability in the course of the disease (9). 
Figure 5
The amelioration of acanthosis nigricans after 6 months of treatment with 
glucocorticosteroids, hydroxychloroquine and metformin.
Figure 6
The extent of psoriatic lesions occurring during follow-up.
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The NIH have recently proposed a treatment regimen 
consisting of rituximab, monthly high-dose glucocorticoids 
and cyclophosphamide, which has proved effective in an 
uncontrolled case series and allowed for discontinuation 
of insulin therapy in the studied patients (9). Combination 
immunosuppressive therapy, described in a prospective 
cohort study, followed by maintenance therapy with 
azathioprine, succeeded in reversing diabetes, signs of 
insulin resistance, and hyperandrogenism in women 
and was relatively safe (9). Unfortunately, the availability 
of rituximab in Poland is restricted in connective tissue 
disorders other than rheumatoid arthritis due to its high 
price. Other reported approaches to treatment have 
included use of prednisolone with hydroxychloroquine 
and azathioprine, plasmapheresis or i.v. immunoglobulin 
(3, 14, 15). In this case, corticosteroids and metformin 
permitted withdrawal of insulin and ameliorated insulin 
resistance symptoms. In several reported TBIR cases, 
remission has occurred spontaneously. In a cohort 
described by Arioglu   et  al., spontaneous remission was 
observed in 33% of patients (1). Time to remission in this 
group ranged between 11 and 48 months and was similar 
to patients treated with immunosuppressive agents. 
Mortality rates in both groups were also comparable. 
However, in the case of coexisting disorders, such as 
connective tissue diseases, immunosuppressive treatment 
may be necessary to ameliorate their symptoms. In the 
presented case, the occurrence of psoriatic arthritis 
with connective tissue disease in 3 years of follow-up 
caused changes to the treatment regimen guided by a 
rheumatologist. Methotrexate with hydroxychloroquine 
helped reduce the severity of autoimmunological 
symptoms with concurrent decrease in the concentration 
of fasting insulin and reduction of hypoglycaemia 
episodes.
In conclusion, the presented case illustrates TBIR 
coexisting with other autoimmune conditions. Beyond 
the clinical signs of insulin resistance, hyperinsulinaemic 
euglycaemic clamp provided standardised biochemical 
confirmation. Targeted individualised therapy with a 
combination of metformin, hydroxychloroquine and 
methotrexate proved effective.
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